Category: Local News

Categories
Environment Local News

St. Michael’s Farm Preserve to host D&R Greenway’s 2021 Masquerade Parade

PRINCETON, N.J. — D&R Greenway Land Trust announces their second Masquerade Parade, to be held at the land trust’s historic St. Michaels Farm Preserve on Sunday, October 31. This drive-through holiday festival is designed for daylight hours on Halloween afternoon from noon until 5:00 p.m.

 

As with last year’s Parade, visitors’ cars will move past exciting stationary ‘floats’ on both sides of the Preserve’s pastoral roadway. These nature ‘floats’ are being designed by local organizations to evoke their mission with the event theme: “Birds, Bats and Bugs… Oh, MY!” Visitors are also invited to decorate their cars to this theme. It was chosen to honor Nature’s small but mighty ambassadors, whose pollinations are essential to life itself. Costumes are welcome and attendees are encouraged to create eye-catching signs revealing their favorite bird, bat or bug, as well as a fun fact about their favorite creature.

 

This Masquerade Parade will be held ‘light rain or shine.’ If severe weather cancels the Parade, we will host a Zoom party on Friday evening, November 5th, in which each Float Group will present their creations, the audience voting for best ‘float!’

 

D&R Greenway Photographers of Preservation will stroll throughout the Parade. Their unique images of the decorated cars, themed ‘floats’, costumed musicians, and St. Michaels’ expansive natural beauty will be available on D&R Greenway’s website during the week following the event. Guests may create free downloads, thus ‘re-living’ this unique day.

 

Vehicles will “line up” in the Hopewell Elementary School parking lot, then migrate to St. Michaels Farm Preserve at the new Princeton Avenue entrance closest to town (Hopewell).

 

Best-selling author/artist Patrick McDonnell, creator of the MUTTS comic strip, is creating an iconic artwork to delight Parade-goers.  Every parade has live music: ours will feature and our very own musician, Bill Flemer of Riverside Bluegrass Band on D&R Greenway’s ‘float’.

 

At departure, each car will receive a nature-themed goody bag of Halloween surprises, including the recently released children’s book, Princesses wear Dresses. With its theme of, “Because what makes a princess a princess is not what she wears, nor how her hair looks, nor what’s on her head,” author Dana Kvalheim and illustrators Lauren Kvalheim and Keeley Nolan convey a significant message with merriment and vigor.

 

To Pre-Register your Carload of Parade-Goers, visit www.drgreenway.org.  Timed tickets are available starting from Noon – 5:00 pm, at $25 per carload. Ticket purchases and Sponsorships support the land trust’s mission of preserving land and inspiring a conservation ethic now and forever.

 

Hikers, dog walkers and bicyclists are asked to access St. Michaels Farm Preserve through the Aunt Molly Road entrance on October 31 as the Princeton Avenue entrance and related trails will be closed to the public for the Parade.

 

Funds from this unique event will expand the land trust’s preservation and stewardship accomplishments in central New Jersey. Public enthusiasm for D&R Greenway’s 44 miles of trails has continuously mounted as COVID 19 requires people to re-imagine their lives and discover new trails, even interact newly with Nature itself. Thanks to the generosity of donors and partners, previous fundraisers and conservation-related events, the preservation of our 317thproperty has soared to over 21,200 New Jersey acres. This achievement secures countless sites for accessible healthy activity, enhancing fitness while protecting and expanding New Jersey’s natural beauty and crucial habitat for wild creatures, such as “Birds, Bars and Bugs… Oh, MY!”.  The vigor of public response to our trails during the COVID challenge demonstrates that “Keeping Open Space Open” is more vital than ever before.

***

BACKGROUND:

 

D&R Greenway Land Trust, an accredited nonprofit, has reached a new milestone of over 21,000 acres of land preserved since 1989. By preserving land for life and creating public trails, it gives everyone the opportunity to enjoy the great outdoors. The land trust’s preserved farms and community gardens provide local organic food for our neighbors—including those most in need. Through strategic land conservation and stewardship, D&R Greenway combats climate change, protects birds and wildlife, and ensures clean drinking water for future generations. D&R Greenway’s mission is centered in connecting land with people from all walks of life.

 

D&R Greenway’s Johnson Education Center, home to its art galleries in Princeton, is currently closed to ensure health and safety due to COVID although its outdoor trails and labyrinth are open. Visit our Facebook and Instagram pages and www.drgreenway.org to learn about the organization’s latest news and virtual programs. D&R Greenway Land Trust, One Preservation Place, Princeton NJ 08540

Categories
Healthcare Local News

Some older adults may qualify to receive Mercer County checks for fresh produce

TRENTON, N.J. – Mercer County Executive Brian M. Hughes reminds older adults in Mercer County of the opportunity to receive checks for fresh-produce through Nov. 30.

 

These payments will enable them to purchase locally grown fresh fruits and vegetables at participating farm stands.

 

“The Senior Farmer’s Market Nutrition Program offers older adults an increased opportunity to make nutritious fresh fruits and vegetables part of their daily eating choices,” said Hughes.

 

“It also helps the older adult who may be struggling financially to get the most for their money.”

 

In an effort keep older adults and their families safe during this pandemic, the staff from the Mercer County Office on Aging have had to change the process for receiving checks.

 

Mercer County residents age 60 and over can receive five (5) $6.00 checks redeemable for fresh produce at participating farmers markets/farm stands across the county.

 

This year, each person will receive the  five $6 checks for a total $30 that are valid through November.  Checks will be distributed on a first-come, first-served basis.

 

Please call 609-989-6661 and speak with a staff member or leave a message with your phone number so the Office on Aging can return the call.

 

When you call the office, be prepared to:

  • Provide your name and address to verify you live in Mercer County
  • State your date of birth to verify you are 60 years of age and older
  • Verify that your income is within the eligibility qualifications listed below:

A single person’s income must not exceed $23,606 per year or $1,968 monthly; a couple’s income must not exceed $31,894 per year or $2,658 monthly.  

 

The Office on Aging staff will mail the checks directly to your address. The checks are valid through Nov. 30, 2021, but distribution of the checks ends Sept. 30, so please call now.

Categories
Business Local News

Billtrust named one of ‘New Jersey’s Best Places to Work’ for third consecutive year

NJBIZ Recognizes B2B Accounts Receivable Automation and Integrated Payments Leader

LAWRENCEVILLE, N.J. — (BUSINESS WIRE) — Billtrust (NASDAQ: BTRS), a B2B accounts receivable automation and integrated payments leader, announced today it has been named among New Jersey’s 2021 Best Places to Work by NJBIZ, a leading business journal. Headquartered in Lawrenceville, NJ, Billtrust was named in the 250+ employee large company category. This is the third consecutive year Billtrust has been recognized and the seventh time since the award was inaugurated.

“We’re very proud to again be named one of New Jersey’s top employers,” said Jeanne O’Connor, Chief Talent Officer at Billtrust. “Billtrust offers a supportive work environment that gives everyone equal opportunity, access to resources and a sense of belonging.”

The NJBIZ honor comes during a year in which Billtrust became a public company and began trading on the Nasdaq Global Select Market and the Nasdaq Capital Market. It also introduced the next major version of its Business Payments Network (BPN), an open network supporting buyers and suppliers allowing both accounts payable and accounts receivable platforms to exchange invoices, payments and remittance data.

NJBIZ Best Places to Work honorees are decided based upon their participation in the Best Places to Work survey from the BridgeTower Media firm Best Companies Group. The program confidentially collects data, allowing workers to comfortably share feedback about their employers.

 

About Billtrust

Billtrust (NASDAQ: BTRS) is a leading provider of cloud-based software and integrated payment processing solutions that simplify and automate B2B commerce. Accounts receivable is broken and relies on conventional processes that are outdated, inefficient, manual and largely paper based. Billtrust is at the forefront of the digital transformation of AR, providing mission-critical solutions that span credit decisioning and monitoring, online ordering, invoice delivery, payments and remittance capture, invoicing, cash application and collections. For more information, visit Billtrust.com.

 

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward looking statements are subject to a number of risks and uncertainties, including those factors discussed in the Company’s filings with the SEC, including those under the header “Risk Factors” in the Registration Statement on Form S-4 filed with the SEC by South Mountain Merger Corp. on October 26, 2020, as amended. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently does not know or that they currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company’s expectations, plans or forecasts of future events and views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts

Media Contact: Meredith Simpson, Msimpson@Billtrust.com

Categories
Farewell Services Local News

ALIFE Church family in Trenton is mourning the loss of a dear pastor

Abiding Love International Fellowship (ALIFE) church has lost one of their beloved and dear Pastor Sandra Giudice.

 

Born in 1942, Giudice will be laid to rest tomorrow in Lawrenceville, N.J. Church services for her funeral will start at 11 a.m. Wednesday at ALIFE church.

 

She is survived by her granddaughter, Daniella; a grandson; a great grandson; and other family members.

 

Arrangements for her funeral is being conducted by Poulson & Van Hise Funeral Home at 650 Lawrenceville Road, Lawrenceville, N.J. Viewing is from 5 to 7 p.m. Tuesday at the funeral home.

Categories
Local News Science

Bristol Myers Squibb shares research supporting correlation between New York Heart Association functional class (NYHA class) and mortality in obstructive hypertrophic cardiomyopathy

Data presented at Heart Failure Society of America Annual Scientific Meeting show worse NYHA class correlates with increased mortality risk among patients with obstructive hypertrophic cardiomyopathy (obstructive HCM)

 

PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #Cardio—Bristol Myers Squibb (NYSE: BMY) today announced findings from a global real-world evidence study that the risk of mortality increases with worse New York Heart Association functional class (NYHA class) for patients with obstructive hypertrophic cardiomyopathy (obstructive HCM). While other studies have documented this association in HCM, this study represents one of the largest, multi-centered studies that specifically focuses on the obstructive HCM patient population.

“These data demonstrate the importance of assessing NYHA functional class in obstructive HCM patients,” said Neal Lakdawala, MD, cardiovascular medicine specialist at Brigham and Women’s Hospital and lead author on the study. “We should determine the impact of therapies for obstructive HCM on patients’ overall prognosis.”

 

 

Over a median follow-up of 3.9 years, the data show a 5% mortality rate in obstructive HCM patients initially classified as NYHA class I, 9% in class II, and 13% in class III/IV. Risks of all-cause mortality and the composite outcome of death or heart transplant increased with worse NYHA class at baseline (p<0.001). The study was conducted in partnership with the Sarcomeric Human Cardiomyopathy Registry (SHaRe) and presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting taking place from September 10 to 13, 2021.

 

 

The full data presentation will be available starting September 10, 2021, 6:15 p.m. – 7:15 p.m. MT on the HFSA website for registered attendees.

 

 

“As approximately half a million people are affected by obstructive HCM worldwide, these data on the association between mortality and NYHA class in obstructive HCM patients are critical globally,” said Mitch Higashi, vice president of U.S. Health Economics and Outcomes Research, Bristol Myers Squibb. “The insight provided by these real-world data in identifying at-risk patients supports improved patient outcomes as well as healthcare efficiencies overall.”

 

 

About the Study

The study analyzed 2,495 obstructive HCM patients with a mean age of 47.6 years at diagnosis, 42% of whom were female. Patient characteristics varied across NYHA class. The Sarcomeric Human Cardiomyopathy Registry (SHaRe) enrolled patients from 10 HCM specialty centers worldwide. The study used data through March 2019, analyzing patients ≥18 years old with obstructive HCM (left ventricular outflow tract (LVOT) peak gradient >30 mmHg or septal reduction therapy) and documentation of NYHA class. Patients were followed from the date of index NYHA class assessment (first documentation of NYHA class I, II, III or IV) to last SHaRe visit or death. The risks of all-cause mortality and a composite endpoint of death and heart transplant were compared across index NYHA classes using log-rank tests.

 

 

About Obstructive Hypertrophic Cardiomyopathy

Obstructive hypertrophic cardiomyopathy (obstructive HCM), the most common type of HCM, is a chronic, progressive disease in which the heart muscle becomes abnormally enlarged or thick causing the left ventricular outflow tract (LVOT) where blood leaves the heart to become obstructed by the enlarged heart muscle. As a result, obstructive HCM can lead to debilitating symptoms for patients and has also been associated with increased risks of atrial fibrillation, stroke, heart failure and sudden cardiac death.

The most frequent cause of obstructive HCM is mutations in the heart muscle proteins of the sarcomere and as many as 50% of patients have a hereditary predisposition to the disease. Obstructive HCM is estimated to affect 400,000-600,000 people worldwide, however many patients remain undiagnosed and/or asymptomatic.

 

 

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

 

 

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that mavacamten may not receive regulatory approval for the indication described in this release in the currently anticipated timeline or at all, any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether such product candidate for such indication described in this release will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2020, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

corporatefinancial-news

Contacts

Bristol Myers Squibb

Media Inquiries:
Media@bms.com

Susan Francis

Susan.Francis@bms.com
609-529-0676

Investors:
Tim Power

Timothy.Power@bms.com
609-252-7509

Categories
Local News Science

UroGen Pharma to present at the H.C. Wainwright 23rd Annual Global Investment Conference

PRINCETON, N.J. — (BUSINESS WIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on-demand via the conference portal and through the Investors section of UroGen’s website, www.urogen.com, beginning at 7:00 a.m. Eastern Time on Monday, September 13, 2021. A replay of the webcast will be available on the website for approximately 30 days.

 

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

Contacts

INVESTOR CONTACTS:
Lee Roth

lroth@burnsmc.com
212-213-0006

Categories
Local News Weather

Hughes urges residents, businesses to register storm damage information

TRENTON, N.J. – Following Tropical Storm Ida, Mercer County Executive Brian M. Hughes wants county residents and business owners to report damages sustained from storm last week via state portal.

 

Hughes is urging those impacted to report their damages at www.nj.gov/ida, which is the State of New Jersey’s data collection portal.

 

Mr. Hughes said that registering damage on the state portal will help FEMA evaluate the county for potential assistance. The portal will record basic information including name, location, damages and cost, and need from impacted residents and businesses.

 

“FEMA is still performing its assessment with county and state guidance, and it’s premature to say Mercer will be excluded from the Major Disaster Declaration,” Mr. Hughes said.

 

“Our Office of Emergency Management staff toured the county with FEMA representatives to survey the damage, and it certainly was extensive in a number of our communities.”

 

County properties that sustained storm damage include the Park Commission’s Howell Living History Farm, Mercer County Park, golf courses and trail systems; County roadways and eight bridges and culverts, Mr. Hughes said.

 

Small businesses and most private nonprofit organizations in Mercer County are eligible to apply for Economic Injury Disaster Loans from the Small Business Administration. For information, visit https://disasterloanassistance.sba.gov/ela/s/.

 

Residents in need of assistance with damage from Tropical Storm Ida may call a Home Cleanup Hotline at 844-965-1386 and speak to volunteers from local relief organizations and community groups that may be able to assist with cutting fallen trees, removing drywall, flooring, and appliances, tarping roofs, and mitigating mold. The hotline will remain open through Sept. 17.

 

Also, note that Mercer County has now been added to the list of New Jersey counties to receive disaster relief from FEMA.

Categories
Healthcare Local News

More than 230 Bristol Myers Squibb employees pedal across the U.S. to advance cancer research in Seventh Annual Coast 2 Coast 4 Cancer Ride

Riders aspire to raise more than $1 million for the V Foundation for Cancer Research and make a profound difference for patients and families touched by cancer

 

PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #C2C4C–Today, Bristol Myers Squibb (NYSE:BMY) employee Mark DeLong is joining more than 230 of his colleagues in Coast 2 Coast 4 Cancer, an epic ~3,000-mile cycling event on two unique routes (~6,000 miles total) to raise funds for the V Foundation for Cancer Research. Like many of the riders, DeLong has been personally affected by cancer – first when he lost his 16-year-old son Peter to Ewing’s sarcoma, and years later when he was diagnosed with an aggressive form of prostate cancer himself. The ride begins today from Cannon Beach, Ore., and concludes on October 1 in Long Branch, N.J.


“While my son is no longer with us, his spirit and outlook that helped him bravely fight his cancer battle remain with me, and I know every day is an absolute gift,” said DeLong. “I try to give back where I can, for every patient who may need the breakthroughs that come from cancer research.”

 

Each year, the goal of the Coast 2 Coast 4 Cancer ride is to raise funds for the V Foundation for Cancer Research, a charitable organization dedicated to achieving Victory Over Cancer®, to support groundbreaking research that aims to make a profound difference for patients and their families. The money raised is matched dollar-for-dollar by Bristol Myers Squibb, with a maximum donation of up to $500,000.

 

“Patients are at the center of everything we do, and as we work to drive progress in cancer research, we know we can’t do it alone,” said Adam Lenkowsky, Senior Vice President, General Manager of U.S. Cardiovascular, Immunology, and Oncology, Bristol Myers Squibb. “The V Foundation has been a longstanding partner of Bristol Myers Squibb and we are proud to catalyze their efforts to fund game-changing research and all-star scientists to accelerate victory over cancer and save lives. Personally, I’m riding for my father-in-law who lost his battle with lung cancer.”

 

Since the 2020 Coast 2 Coast 4 Cancer ride was postponed due to COVID-19, a record 18 teams are participating in this year’s ride with the 2020 and 2021 teams riding concurrently – one on a northern route and one on a southern route – all meeting at the New Jersey shore. Given the evolving COVID-19 environment, Bristol Myers Squibb has kept riders’ safety a top priority, allowing participants to train virtually and will adhere to COVID-19 guidelines along the ride routes.

 

The Coast 2 Coast 4 Cancer tradition began in 2014 when a group of oncology employees in the U.S. were compelled to do more for those impacted by cancer. Since then, more than 530 Bristol Myers Squibb employees have volunteered their personal time to fundraise and extensively train for the ride, resulting in more than $7.15 million for cancer research. Some of the riders have been diagnosed with cancer, while others are riding in honor of loved ones affected by the disease.

 

“People living with cancer faced a year of unprecedented challenges, while the disruptive impact of the COVID-19 pandemic threatened the innovation researchers have worked so hard to advance,” said Shane Jacobson, Chief Executive Officer of the V Foundation for Cancer Research. “Now more than ever, the ongoing fight against cancer depends on groundbreaking research and sustained collective action. We are committed to funding the scientists working at the front lines of cancer research and honored to receive such meaningful support from Bristol Myers Squibb.”

 

In addition to Coast 2 Coast 4 Cancer in the U.S., the Bristol Myers Squibb global workforce demonstrates its long-standing commitment to cancer research with Country 2 Country 4 Cancer (Europe). After four successful years of the effort abroad, more than 150 Bristol Myers Squibb employees will set out to ride in-country routes in Germany, Switzerland, Italy, France, Spain, Belgium, and the United Kingdom, for nearly 3,000 kilometers total this September. This epic cycling event will raise funds for cancer research and European cancer organizations who are members of the Union for International Cancer Control (UICC).

 

For more information or to support the riders in the 2021 Coast 2 Coast 4 Cancer ride, please visit cancerbikeride.org or follow the ride on Facebook, Twitter and LinkedIn by using #C2C4C.

 

About Bristol Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

 

About the V Foundation for Cancer Research

The V Foundation for Cancer Research was founded in 1993 by ESPN and the late Jim Valvano, legendary North Carolina State University basketball coach and ESPN commentator. The V Foundation has funded more than $260 million in game-changing cancer research grants nationwide through a competitive process strictly supervised by a world-class Scientific Advisory Committee. Because the V Foundation has an endowment to cover administrative expenses, 100% of direct donations is awarded to cancer research and programs. The V team is committed to accelerating Victory Over Cancer®. To learn more, visit v.org.

philanthropy-news

Contacts

Bristol Myers Squibb

Media:
media@bms.com

Heather Acker

973-713-6137

heather.acker@bms.com

Investors:
Tim Power

609-252-7509

Timothy.Power@bms.com

Categories
Local News Science

Gennao Bio appoints Gary Sender to board of directors

HOPEWELL, N.J. — (BUSINESS WIRE) — Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the appointment of Gary Sender to its board of directors. Mr. Sender will chair the Audit Committee and the Compensation Committee.

“We are proud to further bolster our board of directors with the appointment of Gary, a highly regarded leader in the life sciences industry who will serve as our Audit and Compensation Committee Chair,” said Stephen Squinto, Ph.D., chief executive officer and chair of the board of Gennao Bio. “Gary’s business acumen and expertise in corporate financial management and build-out will be beneficial as we continue on a trajectory of rapid growth and development.”

 

“Gennao’s strong leadership team, broad-based technology platform and commitment to transforming genetic medicine make this a very compelling opportunity,” stated Mr. Sender. “I look forward to assisting the Company develop and fund a robust pipeline of GMAB therapeutics to benefit patients across a number of oncology and rare skeletal muscle diseases.”

 

Mr. Sender is a seasoned executive and board member with more than 25 years of financial leadership experience in organizations ranging from large, multi-national pharmaceutical firms to early-stage biotechnology companies. He was chief financial officer of Nabriva Therapeutics plc, a publicly traded biopharmaceutical company, from 2016 until March 2021 when he retired. Prior to Nabriva, Mr. Sender served as chief financial officer and executive vice president at Synergy Pharmaceuticals from 2015 to 2016, and as senior vice president, finance at Shire plc from 2009 until 2015, supporting its specialty pharmaceuticals business and subsequently its global commercial businesses. He was also the founding chief financial officer of Tengion, Inc., and spent 15 years in several leadership roles within Merck. Mr. Sender received a B.S. in Finance from Boston University and an M.B.A. in Finance from Carnegie‑Mellon University.

 

About Gennao Bio

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.

Contacts

Investors
Joe Rayne

JRayne@gennao.com
617-538-1716

Media
Marcy Nanus

MNanus@gennao.com
516-901-2584

Categories
Environment Local News

D&R Greenway plans autumn native plant sale dates for ‘keeping the garden in The Garden State’

PRINCETON, N.J. — D&R Greenway Land Trust announces dates for its popular autumnal native plant sale that will soon open to the public in Princeton.

Coreopsis
— by Tina Notas

 

The event will be opened to the public Thursday, Sept. 16, from 5 – 6:30 p.m.; Friday, Sept. 17, from 5 – 6:30 p.m.; and Saturday, Sept. 18, from 9:00 until 11:00 a.m., at the Johnson Education Center, One Preservation Place in Princeton.

 

“Fall is an ideal time for planting shrubs and new trees, as they establish strong root systems before winter, well ahead of the stress of summer heat. Significantly, local plants require less maintenance in terms of fertilizer, water and pesticides,” states Director of Land Stewardship for D&R Greenway Tina Notas.

 

She explains that,  the land trust’s Native Plant Nursery specimens are grown from locally sourced starter plants free of nicotinoid insecticides which harm pollinators. Local plants are conditioned to survive regional stresses. Planting natives that evolved locally turns home gardens into habitat.

 

“Our Nursery, in front of which the sales are held, is an outdoor space. Visitors selecting their plants must wear masks and maintain social distancing,” she states.  As in earlier COVID-affected events, D&R Greenway Staff monitors ‘entrance,’ as needed.

 

D&R Greenway’s Native Plant Nursery availability has over 50 varieties of plants of the region. They are selected for health, for beauty and to provide shelter and food for regional birds, insects and butterflies. Our trees, shrubs, perennial wildflowers, grasses, sedges & ferns are grown either on-site or purchased from reputable nearby native plant growers. Our flora not only support New Jersey’s unique environment, but also D&R Greenway’s preservation and stewardship mission.

 

Notas reveals her enthusiasm for her very successful Nursery sales, despite pandemic realities:

 

Cardinal flower
— by Tina Notas

“We are delighted to open our native plant nursery to the public, so that local gardeners may safely choose our vibrant native flora. Our broad array of plants summons specific creatures dependent upon our unique local ecosystem, in both breeding and migratory seasons.”

 

An up-to-date inventory is at the D&R Greenway’s Native Plant Nursery’s website: https://drgreenway.org/shop/native-plants/ Available trees and shrubs include oaks, ironwood, delicious local fruiting trees including pawpaw, serviceberry, beach plum; as well as buttonbush, red buckeye, spicebush (earliest spring flowerlets and home of spicebush swallowtail butterfly), witch hazel (which blooms in winter), dogwood and bayberry. Among our native flowers are blue flag iris, mountain mint, goldenrod (this important pollinator plant bears heavy pollen, which falls to the ground, does not travel by air, does not generate allergies), subtle foxglove beardtongue, towering Joe Pye weed and the exquisite blue lobelia.

 

The Johnson Education Center’s ca. 1900 barn is not currently open to the public though the land trust’s popular preserves and trails remain open for public enjoyment. The land trust has been careful to put practices in place that safeguard purchasers and staff, yet enabling gardeners to enjoy the spring planting tradition.

Bee balm
— by Tina Notas

***

 

BACKGROUND

D&R Greenway Land Trust, an accredited nonprofit, has saved over 21,000 acres of New Jersey land since its 1989 founding. D&R Greenway’s mission is connecting land with people from all walks of life. Preserving land for life and creating public trails grants everyone the opportunity to enjoy the great outdoors.

 

The land trust’s preserved farms and community gardens provide local, organic food for neighbors—including those in need. D&R Greenway’s strategic land conservation and stewardship combat climate change, protect wildlife, and ensure clean drinking water for future generations.

 

Our outdoor trails and labyrinth are open. Visit our Facebook and Instagram pages and www.drgreenway.org to learn about the organization’s latest news and virtual programs. D&R Greenway Land Trust, One Preservation Place, Princeton NJ, 08540. The best way to reach D&R Greenway Staff during the COVID pandemic is by e-mail, or by calling D&R Greenway at 609-578-7470.